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DObjective: The impact on survival of tricuspid regurgitation (TR) after redo valvular surgery in patients with
previous mitral valve replacement (MVR) is unclear.
Methods: We retrospectively analyzed 118 consecutive patients undergoing redo valvular surgery after MVR
over a 20-year period. We determined the impact of TR after redo valvular surgery on survival and clinical
factors that were associated with TR of 2þ or higher. The mean follow-up period was 7.1  6.5 years.
Results: Overall hospital mortality was 8.5% (10 of 118). Logistic regression analysis revealed that cardiopul-
monary bypass duration (odds ratio, 1.025; P ¼ .0270) was an independent risk factor for hospital death. There
were 25 late deaths. Survival after 5, 10, and 15 years was 77.5% 4.2%, 68.5% 5.1%, and 58.8% 6.3%,
respectively. Multivariate Cox regression analysis showed that TR less than 2þ at discharge was a predictor of
late survival (hazard ratio, 0.043; P<.0382), whereas age, female sex, left ventricular end-diastolic dimension,
and cardiopulmonary bypass duration were predictors of late death. Survival for patients with TR less than 2þ
versus 2þ or higher after redo surgery were 91.4%  3.4% versus 59.5%  11.9% at 5 years and 81.1% 
5.3% versus 52.1%  12.5% at 10 years, respectively (log-rank P ¼ .0285). Logistic regression analysis indi-
cated that preoperative TR (odds ratio, 3.718; P¼ .0044) and chronic obstructive pulmonary disease (odds ratio,
28.576; P ¼ .0154) were independent risk factors for TR of 2þ or higher after redo surgery.
Conclusions: Survival in patients with TR of 2þ or higher after redo valvular surgery was poor. The results of
this study suggest that it is important to maintain a postoperative TR less than 2þ to improve long-term survival.
(J Thorac Cardiovasc Surg 2014;148:1983-8)Late tricuspid regurgitation (TR) after mitral valve replace-
ment (MVR) is a significant problem for cardiac surgeons.
Although functional TR might improve after surgical
correction of left-sided valve lesions,1 residual significant
TR has been reported to progress in about half of patients.2
TR has harmful effects on clinical outcomes including
biventricular heart failure and long-term survival.3 Further-
more, 1 report showed that moderate or greater TR is asso-
ciated with worse survival regardless of left ventricular
ejection fraction or increased pulmonary artery pressure.4
Tricuspid valve surgery (TVS) as a reoperation carries
high operative mortality. Pfannmuller and colleagues5 re-
ported that the overall 30-day mortality was 14.6% and
the 2-year survival was 63.0% 5.5%.5 McCarthy and col-
leagues6 found that 30-day mortality after reoperation was
32% and survival at 1 and 3 years was 31% and 19%,e Department of Cardiovascular surgery, Kobe City Medical Center General
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The Journal of Thoracic and Carrespectively. These results indicate that redo TVS may be
associated with high mortality; thus, it is difficult to make
a decision to intervene for TR after valvular surgery.
The impact on survival of TR after redo valvular surgery
in patients with previous MVR is unclear. The relative
importance of residual TR might differ between a first
and second operation.
Therefore, we analyzed our 20-year experience of redo
valvular surgery after MVR to determine the impact of
TR after redo valvular surgery on early and long-term
survival.PATIENTS AND METHODS
This study was approved by the institutional review board at our
institute.
We analyzed 118 consecutive patients (41 were males [35%]) undergo-
ing redo valvular surgery at our institute over a 20-year period from January
1990 to December 2010.We retrospectively reviewed their medical records
in accordance with the Society of Thoracic Surgeons guidelines.7 In more
than 90% of patients, a single surgeon performed the redo operation.
All patients had undergone MVR with or without aortic valve replace-
ment. Table 1 shows the preoperative characteristics of the patients
included in the study. Atrial fibrillationwas present in 80 (68%) of patients.
Fifty-two (44%) patients were in New York Heart association (NYHA)
functional class III or IV. About 30% of the patients had undergone previ-
ous valvular surgery. Previous operations included single MVR in 104
(88%) and MVR plus aortic valve replacement in 14 (12%). The main
cause of redo valvular surgery was structural valve deterioration in the
mitral position.diovascular Surgery c Volume 148, Number 5 1983
Abbreviations and Acronyms
CI ¼ confidence interval
COPD ¼ chronic obstructive pulmonary disease
MVR ¼ mitral valve replacement
NYHA ¼ New York Heart association
TR ¼ tricuspid regurgitation
TVR ¼ tricuspid valve replacement
TVS ¼ tricuspid valve surgery
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D TR was graded on transthoracic echocardiography as 0 for no regurgi-
tation, 1þ for mild regurgitation, 2þ for moderate regurgitation, 3þ for
moderately severe regurgitation, and 4þ for severe regurgitation.6
TR grade as an end point was assessed at discharge not late recurrent TR
on transthoracic echocardiography.
Follow-up
Patients were followed up in the outpatient clinic every 6 or 12 months.
The decision for redo surgery was made based on the examination in the
outpatient clinic. The mean follow-up period was 7.1  6.5 years (range,
0.04-22.3 years).
Statistical Analysis
All statistical analyses were performed with StatView version 5.0 soft-
ware (SAS Institute, Inc, Cary, NC). Categorical variables were analyzed
using the c2 test and are expressed as percentages. Continuous variables
were analyzed by Student paired or unpaired t tests and are expressed as
the mean  standard deviation. The Kaplan-Meier method was used to
estimate long-term survival. Univariate analysis was performed using the
Fisher exact probability and t tests. Variables with a univariate probability
value of 0.2 or less were included in multivariate logistic regression
analysis to determine the independent factors for short-term (hospital) sur-
vival. Cox regression analysis was also used to identify the predictors of
long-term survival.RESULTS
Early Outcomes and Risk Factors for Hospital
Mortality
Overall hospital mortality was 8.5% (n¼ 10). The causes
of hospital death were arrhythmia (n ¼ 3), multiorgan fail-
ure (n¼ 3), low output syndrome (n¼ 2), bleeding (n¼ 1),
and sepsis (n ¼ 1). The major postoperative complications
included exploration for bleeding (n ¼ 5), stroke (n ¼ 3),
reintubation (n ¼ 7), ventilator support for 72 hours or
longer (n ¼ 12), gastrointestinal bleeding (n ¼ 2), newly
required dialysis (n ¼ 3), and pacemaker implantation
(n ¼ 5). The mean intensive care unit stay was 7.1  13.1
days.
Logistic regression analysis revealed that cardiopulmo-
nary bypass duration (odds ratio, 1.025; P ¼ .0270; 95%
confidence interval [CI], 1.003-1.047) was an independent
risk factor for hospital mortality (Table 2). NYHA func-
tional class III or IV, chronic obstructive pulmonary disease
(COPD), the number of redo surgeries, and pulmonary
hypertension were not significant risk factors.1984 The Journal of Thoracic and Cardiovascular SurLong-Term Survival
During amean follow-up period of 7.1 6.5 years (range,
0.04-22.3 years), there were 25 deaths. The cause of death
included heart failure (n ¼ 4), sudden death (n ¼ 3), multi-
organ failure (n ¼ 2), bleeding (n ¼ 2), arrhythmia (n ¼ 1),
prosthetic valve endocarditis (n ¼ 1), and others (n ¼ 12).
Kaplan-Meier estimates of cumulative survival are
shown in Figure 1. Survival at 5, 10, and 15 years was
77.5%  4.2%, 68.5%  5.1%, and 58.8%  6.3%,
respectively.
Multivariate Cox regression analysis showed that the
only predictor of late survival was TR less than 2þ at
discharge (hazard ratio, 0.043; 95% CI, 0.002-0.843;
P< .0382). In contrast, age, female sex, left ventricular
end-diastolic dimension, and cardiopulmonary bypass dura-
tion were predictors of late death (Table 3).Survival Based on TR Grade Before Redo Surgery
To investigate the impact of preoperative TR on survival,
we compared survival based on the preoperative grade of
TR (Figure 2). Although there was no significant effect of
TR grade on survival, increasing severity of TR tended to
be associated with worse survival (log-rank P ¼ .0649).
With regard to TVS for TR, 49 patients underwent TVS
in this study. We analyzed the usefulness of TVS for TR
in patients with a preoperative grade of TR of 2þ or higher.
There was no significant difference in late survival between
patients with and without TVS (70.4% 8.9% vs 87.8%
8.1% at 5 years, log-rank P ¼ .1054).Survival Based on TRGrade at Discharge After Redo
Surgery
To examine the impact of TR after redo surgery on sur-
vival, we compared survival based on TR grade at discharge
on transthoracic echocardiography (Figure 3). Increasing
TR severity was associated with worse survival (log-rank
P ¼ .0073).
Although we compared postoperative TR 4þ (n ¼ 5)
with TR 2þ (n ¼ 19) with regard to survival as a subgroup
analysis, there was no statistically significant difference in
survival between patients with TR 4þ and 2þ (log-rank
P ¼ .1225).
Based on these results, the entire study cohort was classi-
fied into 2 groups: TR grade at discharge less than 2þ and
2þ or higher; long-term survival was compared between the
groups.
Survival between the groups with TR less than 2þ versus
TR 2þ or higher after redo surgery groups was 91.4% 
3.4% versus 59.5%  11.9% at 5 years and 81.1% 
5.3% versus 52.1%  12.5% at 10 years, respectively
(log-rank P ¼ .0285) (Figure 4).
The patient characteristics are summarized in Table 4.
There were no significant differences between the 2 groupsgery c November 2014
TABLE 1. Clinical characteristics of patients (N ¼ 118)
Variables n (%) or mean
Mean age, y  SD 63.2  12.6
Body surface area, m2  SD 1.48  0.16
Male sex 41 (35)
Hypertension 23 (19)
Diabetes mellitus 17 (14)
Hyperlipidemia 10 (8)
COPD 4 (3)
Congestive heart failure 37 (31)
Peripheral artery diseases 4 (3)
Stroke 32 (27)
Hemodialysis 2 (2)
Liver cirrhosis 8 (7)
Coronary artery diseases 4 (3)
Atrial fibrillation 80 (68)
Pulmonary hypertension 30 (25)
NYHA class
I/II (%) 66 (56)
III/IV (%) 52 (44)
Urgency of surgery
Elective (%) 105 (89)
Emergency/urgent (%) 13 (11)
Number of redo surgery
First time 80 (68)
Twice or more 38 (32)
Previous operations
MVR 104 (88)
Mechanical 21 (18)
Biological 83 (70)
þAVR 14 (12)
Causes of redo
SVD 86 (73)
Non-SVD 15 (13)
PVE 9 (8)
Others 8 (7)
SD, Standard deviation; COPD, chronic obstructive pulmonary disease; NYHA, New
York Heart Association; MVR, mitral valve replacement; AVR, aortic valve replace-
ment; SVD, structural valve deterioration; PVE, prosthetic valve endocarditis.
FIGURE 1. Kaplan-Meier curve showing overall survival after redo
surgery. Pts, Patients.
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Dexcept for the body mass index (P ¼ .0480), COPD
(P ¼ .0057), and congestive heart failure (P ¼ .0274).
TVS was performed in 41 patients (44%) with TR less
than 2þ and in 8 (33%) with TR greater than 2þ; the dif-
ference was not significant (P ¼ .3615). TVS consisted ofTABLE 2. Multivariate predictors of hospital mortality and tricuspid
regurgitation grade of 2þ or higher at discharge
Variables Odds ratio 95% CI P value
Hospital mortality
CPB duration 1.025 1.003-1.047 .0270
TR 2þ after redo
Preoperative TR 3.718 1.506-9.175 .0044
COPD 28.576 1.898-430.3 .0154
Congestive heart failure 6.601 0.889-49.014 .0650
CI, Confidence interval; CPB, cardiopulmonary bypass; TR, tricuspid regurgitation;
COPD, chronic obstructive pulmonary disease.
The Journal of Thoracic and Carannuloplasty performed by either suture or a ring in all 49
patients.
Prosthetic valve endocarditis was more common in
the group with TR 2þ or higher (P ¼ .0616). Preoperative
transthoracic echocardiographic data are shown in Table 5.
There was a significant difference in the preoperative TR
grade between the 2 groups (P<.0001). We also analyzed
the risk factors for TR 2þ or higher after redo surgery. Lo-
gistic regression analysis indicated that the preoperative
grade of TR (odds ratio, 3.718; P ¼ .0044) and COPD
(odds ratio, 28.576; P ¼ .0154) were independent risk fac-
tors for TR 2þ or higher. The effect of congestive heart fail-
ure on the group with TR 2þ or higher did not reach
statistical significance (P ¼ .0650).
Freedom From Late Recurrent TR 2þ or Higher
Late recurrent TR was defined as an increase in TR by
more than 1 grade and a final TR grade of 2þ or higher
on late follow-up echocardiography. Patients with a TR
grade of 2þ at both discharge and late follow-up were not
included in the group that developed late recurrent TR 2þ
or higher. Freedom from late recurrent TR 2þ or higher
was 91.5%  3.7% at 5 years and 73.2%  6.5% at 10
years. Freedom from late recurrent TR 2þ or higher at 5
years in patients undergoing De Vega and ring annuloplastyTABLE 3. Multivariate Cox regression analysis for risk factor of late
death
Variables Hazard ratio 95% CI P value
Age 1.741 1.257-2.411 .0008
Female 22.182 2.353-209.1 .0068
LVEDD at discharge 1.706 1.194-2.437 .0034
CPB duration 1.084 1.015-1.158 .0166
TR<2þ at discharge 0.043 0.002-0.843 .0382
CI, Confidence interval; LVEDD, left ventricular end-diastolic diameter; CPB,
cardiopulmonary bypass; TR, tricuspid regurgitation.
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FIGURE 2. Kaplan-Meier curve showing survival based on the grade of
tricuspid regurgitation before redo surgery. Pts, Patients; TR, tricuspid
regurgitation.
FIGURE 4. Kaplan-Meier curves comparing survival between patients
with tricuspid regurgitation less than 2þ and 2þ or higher after redo sur-
gery. Pts, Patients; TR, tricuspid regurgitation.
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(log-rank P>.05).DISCUSSION
The present study describes the negative impact of a TR
grade of 2þ or higher after redo valvular surgery on long-
term survival in patients with previous MVR. Nath and col-
leagues4 found that TR 2þ or higher was associated with
worse survival in a general cohort. Given our results, the
findings of Nath and colleagues4 may also apply to patients
who have undergone redo valvular surgery.
The negative impact of TR grade of 2þ or higher suggests
that there should be aggressivemanagement of TR after redo
valvular surgery to achieve a TR grade less than 2þ.
In our cohort, the risk factors for TR 2þ or higher after
redo surgery were preoperative TR grade and COPD. A
relationship between COPD and pulmonary hypertension
has been described previously.8 Furthermore, pulmonary
hypertension is an important factor that affects functionalFIGURE 3. Kaplan-Meier curve showing survival based on the grade of
tricuspid regurgitation after redo surgery. Pts, Patients; TR, tricuspid regur-
gitation.
1986 The Journal of Thoracic and Cardiovascular SurTR.9 However, our analysis did not identify pulmonary
hypertension as an independent factor for functional TR.
In our current strategy for treating functional TR, ring an-
nuloplasty is a mandatory procedure. The selection of ring
size is based on the patients’ body surface area. However, if
residual massive TR is recognized on intraoperative transe-
sophageal echocardiography, additional or alternative pro-
cedures might be necessary.
One option to manage residual TR is to perform tricuspid
valve replacement (TVR). In our 20-year experience, TVR
was performed in a few cases and postoperative TR was
moderate or less. Another option is to perform leaflet repair.
We have reported a technique of leaflet augmentation by
glutaraldehyde-treated autologous pericardium for late TR
after cardiac surgery.10 This procedure is useful to prevent
postoperative TR 2þ or higher.
The 5-year survival after TVR was 60%  13% for me-
chanical valves and 56%  6% for bioprosthetic valves
(P ¼ .8).11 Survival for tricuspid valve repair compared
with TVR for late TR was 84.1% versus 69.4% after 1
year and 84.1% versus 60.1% after 3 years, respectively
(log-rank P¼ .043).12 Early and late outcomes for tricuspid
valve repair were better than those for TVR. On the other
hand, there was no significant difference in 10-year survival
between TVR and repair.13 Freedom from reoperation at 5
years occurred in more than 90% of patients with TVR.11
Over our 20-year experience, TVR was performed in only
a few cases in our institute, but TVR itself did not neces-
sarily have worse outcomes. In specific cases such as ste-
notic tricuspid valve, a history of previous TVS, dilated
right ventricle, right ventricular dysfunction, and repeated
cardiac surgery, TVRwas indicated.3 It might be acceptable
to perform TVR in those cases to maintain TR grade at less
than 2þ after redo surgery as mentioned earlier.gery c November 2014
TABLE 4. Comparison between tricuspid regurgitation grade less
than 2 and 2þ or higher after redo surgery
Variables
TR<2þ (n ¼ 94),
n (%)
TR 2þ (n ¼ 24),
n (%) P value
Mean age, y  SD 62.7  13.1 65.5  9.9 .1687
BSA, m2  SD 1.48  0.16 1.47  0.18 .0480
Male sex 32 (34) 9 (38) .7509
Hypertension 19 (20) 4 (17) .6955
Diabetes mellitus 13 (14) 4 (17) .7829
Hyperlipidemia 8 (9) 2 (8) .9778
COPD 1 (1) 3 (13) .0057
Congestive heart
failure
25 (27) 12 (50) .0274
PAD 3 (3) 1 (4) .8137
Stroke 27 (29) 5 (21) .4377
Hemodialysis 1 (1) 1 (4) .2932
Liver cirrhosis 7 (7) 1 (4) .5683
CAD 4 (4) 0 (0) .3039
Atrial fibrillation 61 (65) 19 (79) .1817
NYHA class III/IV 38 (40) 14 (58) .1148
Emergency 11 (12) 2 (8) .6380
Number of redo
twice or more
27 (29) 11 (46) .1094
Previous operations
MVR 84 (89) 20 (83) .4150
MVRþAVR 10 (11) 4 (17) .4150
Causes of redo
SVD 69 (73) 17 (71) .8004
Non-SVD 13 (14) 2 (8) .4706
PVE 5 (5) 4 (17) .0616
Current operations
MVR 78 (83) 22 (92) .2907
AVR 3 (3) 1 (4) .8137
MVRþAVR 12 (13) 0 (0) .0648
TVS 41 (44) 8 (33) .3615
Suture 19 4
Ring 22 4
TR, Tricuspid regurgitation; SD, standard deviation; BSA, body surface area; COPD,
chronic obstructive pulmonary disease; PAD, peripheral artery disease; CAD,
coronary artery disease; NYHA, New York Heart Association; MVR, mitral valve
replacement; AVR, aortic valve replacement; SVD, structural valve deterioration;
PVE, prosthetic valve endocarditis; TVS, tricuspid valve surgery.
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colleagues6 concluded that TR increased over time after
Peri-Guard and De Vega annuloplasty, and these techniquesTABLE 5. Preoperative transthoracic echocardiographic data
Variables TR<2þ (n ¼ 94) TR  2þ (n ¼ 24) P value
LVEF,%  SD 61.6  8.8 57.9  8.9 .7842
LVEDD, mm  SD 45.8  6.5 45.8  7.9 .9032
LVESD, mm  SD 29.5  7.1 29.0  6.8 .3017
LAD, mm  SD 49.6  12.9 46.3  12.8 .6346
RVP, mm Hg  SD 46.2  16.2 45.6  11.1 .8673
TR grade  SD 1.6  1.0 2.4  0.6 <.0001
TR, Tricuspid regurgitation; SD, standard deviation; LVEF, left ventricular ejection
fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular
end-systolic diameter; LAD, left atrium diameter; RVP, right ventricular pressure.
The Journal of Thoracic and Carshould be abandoned. Other review papers have also indi-
cated that ring annuloplasty is superior to De Vega annulo-
plasty.14 Given this evidence and the reproducibility of ring
annuloplasty, artificial ring annuloplasty is an important
surgical option for TVS. In our study, all 49 patients
(42%) who underwent TVS had tricuspid annuloplasty at
the time of redo surgery. Of these, 23 (47%) underwent an-
nuloplasty using the suture technique.
Fukuda and colleagues15 demonstrated the value of the
tricuspid annulus area in healthy individuals. They reported
that both the maximum and minimum tricuspid annulus
areas in patients with TR 2þ or higher were larger than
those values in healthy individuals (P<.05).
Inappropriate ring size selection, which ignores the rela-
tionship between body surface area and tricuspid annulus
area as shown by Fukuda and colleagues15 might be related
to a TR grade of 2þ or higher after redo surgery, leading to
poor long-term survival. In our institute, the prosthetic ring
size is selected based on the patient’s body surface area.
Redo TVS was associated with worse clinical outcomes.
Some studies reported high mortality rates ranging from
13.2% to 37%.5,6,16
Despite the high mortality rate, survivors benefited from
redo surgery and NYHA class at follow-up was better than
that preoperatively.16 Mortality in elective surgery was
much lower than that in emergency surgery (4.0% vs
31.2%; P ¼ .001).5 Park and colleagues3 reported no hos-
pital deaths after redo TVS. Possible reasons for this favor-
able outcome were younger patients compared with
previous reports and the use of aggressive hemofiltration.
Overall in-hospital mortality in our study was 9.4%, which
was lower than that reported previously.
Isolated TVS with minimally invasive access via a right
thoracotomy has been increasingly applied in redo surgery.
An early mortality rate of 4.2% was reported using this
technique. In particular, the mortality rate in elective cases
was 0%.16
The investigators stated that with this technique there is
no need to dissolve adhesions and scar tissue to cannulate
vessels for cardiopulmonary bypass, and this may reduce
the incidence of right-sided dilatation and failure that can
accompany traditional open surgery.5,17
In redo TVS, most patients referred for surgery have
advanced heart failure or end-organ dysfunction.16 The
high mortality and morbidity in redo TVS is believed to
be associated with not only redo TVS itself but also end-
organ dysfunction. It is reasonable to think that surgical
intervention should be earlier rather than later.17 It has
been suggested that significant TR should be operated on
before there is irreversible damage to the right ventricle in
patients with advanced mitral valve disease.3,18
Predictors of early death in a previous study included
advanced age, creatinine levels of 2 mg/dL or higher and
Child-PughC liver cirrhosis.12 In our study, cardiopulmonarydiovascular Surgery c Volume 148, Number 5 1987
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mortality and late death. This result possibly reflects opera-
tive injury to patients because patients who underwent TVS
as a redo surgery had lower organ reserve as mentioned
earlier.
The reason for the worse long-term mortality in patients
with significant TR is possibly because TR is a more sensi-
tive marker of right ventricular dysfunction than visual
interpretation of systolic performance, and the presence of
TRmay mask decreased contractility of the right ventricle.4
Right ventricular function is an important factor affecting
midterm and long-term survival in patients with valvular
diseases.18
In our study, total cumulative survival at 5, 10 and 15
years was 77.5%  4.2%, 68.5%  5.1%, and 58.8% 
6.3%, respectively.
Survival of patients with TR less than 2þ and 2þ or
higher after redo surgery was 91.4%  3.4% versus
59.5%  11.9% at 5 years and 81.1%  5.3% versus
52.1%  12.5% at 10 years (log-rank P ¼ .0285). These
results show the negative impact of TR, in particular a TR
grade of 2þ or higher on survival. Because no previous
studies have reported the effect of TR 2þ or higher on sur-
vival after redo surgery, we could not compare our results
with previous reports. Park and colleagues3 reported that
survival at 5 years was 93% for both TVR and tricuspid
repair. Chen and colleagues12 reported 3-year survival of
76.4% after TVS. Despite differences in patients’ back-
grounds, survival in patients with TR 2þ or higher after
redo surgery in the present study was worse compared
with the outcomes in these previous studies.
Limitations
The present study has been some important limitations. It
was a retrospective study rather than a randomized trial.
Because surgical indications and techniques such as suture
and ring annuloplasty for TR after MVR were not uniform,
TVS was not performed in some patients with a preopera-
tive TR grade of 2þ or higher. This fact might have affected
postoperative TR and long-term survival.
However, we included a relatively large number of pa-
tients (n ¼ 118) who underwent redo valvular surgery after
MVR and had a long duration of follow-up. In addition, no
previous studies have described the impact of TR after redo
surgery on survival. Therefore, our study provides impor-
tant information not only for cardiac surgeons but also for
cardiologists regarding the negative impact of TR after
redo valvular surgery on survival. Our results draw attention
to the presence of TR in redo surgery in the setting of
currently available transcatheter aortic valve implantation
techniques.1988 The Journal of Thoracic and Cardiovascular SurCONCLUSIONS
Survival in patients with a TR grade of 2þ or higher after
redo surgery was poor. The appropriate management of TR
postoperatively may improve long-term survival. For pa-
tients with multiple risk factors for the development of
TR 2þ or higher after redo valvular surgery, surgical inter-
ventions should be considered at the time of redo surgery to
prevent postoperative TR 2þ or higher.
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